Reuters: Health
Regeneron Pharmaceuticals Inc said on Thursday its experimental treatment for a very rare genetic bone disorder showed a nearly 90% reduction in new lesions compared to placebo, in a mid-stage study.
Regeneron's bone disorder drug reduces lesions in mid-stage study
Regeneron's bone disorder drug reduces lesions in mid-stage study
Reuters: Health
Regeneron Pharmaceuticals Inc said on Thursday its experimental treatment for a very rare genetic bone disorder showed a nearly 90% reduction in new lesions compared to placebo, in a mid-stage study.
Reuters: Health
Regeneron Pharmaceuticals Inc said on Thursday its experimental treatment for a very rare genetic bone disorder showed a nearly 90% reduction in new lesions compared to placebo, in a mid-stage study.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment